An engineered linear cap-independent mRNA vaccine with intrinsic adjuvanticity induces potent anti-tumor immunity in mice - PubMed
4 hours ago
- #immune stimulation
- #mRNA vaccine
- #cancer immunotherapy
- Engineered linear cap-independent mRNA (LciRNA) vaccine platform developed for cancer treatment.
- LciRNA combines UPA protective sequence with Enterovirus A internal ribosome entry site for stability and immune stimulation.
- UPA sequence includes xrRNA and PABP motif to resist exonuclease decay and enhance in vivo expression without 5' capping.
- LciRNA intrinsically activates immune responses by engaging pattern-recognition receptors and promoting dendritic cell maturation.
- Demonstrated potent anti-tumor immunity in murine melanoma and HPV-associated tumor models.
- Superior tumor control achieved through strong systemic and intra-tumoral T cell responses.
- Highlights cost-effective design with coupled immune stimulation and translation as a future paradigm for mRNA vaccines.
- Patent application filed for LciRNA platform by inventors S.H. and H.Y.